Work

Real-World Treatment Duration With First-line Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A National Electronic Health Record Study

Year: 2026

Type: article

Study design: Observational Study

Source: Clinical Genitourinary Cancer

DOI: 10.1016/j.clgc.2026.102652

Authors: Melanie Mayer, Nicholas J. Seewald, Ernesto Ulloa-Pérez, Blanca Homet Moreno, Chethan Ramamurthy, Aram Babcock, Haojie Li, Ronac Mamtani

Institutions: University of Pennsylvania, Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Merck Sharp and Dohme

OpenAlex ID: W7203623682

FWCI:

Cites: 6

Cited by:

Related to: 10